Core Insights - Ascend Wellness Holdings, Inc. reported Q1 2025 net revenue of $128.0 million, a decrease of 5.9% quarter-over-quarter, with retail revenue down 6.6% and wholesale revenue down 4.4% [1][7][8] - The company generated positive cash from operations of $5.9 million, marking the ninth consecutive quarter of positive operating cash flow [1][11] - The company ended Q1 2025 with $100.0 million in cash and cash equivalents, reflecting a sequential increase of $11.7 million [1][11] Business Highlights - The company is focused on executing a densification strategy aimed at increasing store count by approximately 50% in the medium term, targeting ten new stores in 2025 [6][7] - New product launches and store openings are anticipated in the coming months to enhance consumer experience and expand access [6][7] Financial Highlights - Adjusted EBITDA for Q1 2025 was $27.0 million, representing a margin of 21.1%, a decrease of 10.7% from the previous quarter [7][11] - The net loss for Q1 2025 was $19.3 million, compared to a net loss of $16.8 million in Q4 2024 [7][10] - Total general and administrative expenses decreased to $37.1 million, or 29.0% of revenue, down from $40.8 million, or 30.0% of revenue, in Q4 2024 [10][11] Revenue Breakdown - Total net revenue of $128.0 million included retail revenue of $84.4 million and wholesale revenue of $43.6 million, both showing declines due to competitive pressures and pricing [7][8] - Gross profit for Q1 2025 was $39.6 million, or 30.9% of revenue, down from $46.9 million, or 34.5% of revenue, in Q4 2024 [9][11] Cash Flow and Balance Sheet - Free Cash Flow for Q1 2025 was $1.2 million, calculated as cash from operations minus capital expenditures [5][11] - Net Debt as of March 31, 2025, was $233.0 million, reflecting total debt less cash and cash equivalents [4][11] - The company launched a share buyback program in January 2025, repurchasing 1,571,500 shares by April 30, 2025 [7]

Core Viewpoint - Glass House Brands Inc. is hosting its 4th Annual Investor Sesh to showcase its growth and engage with shareholders, emphasizing transparency and appreciation for their support [1][2]. Company Overview - Glass House Brands is recognized as one of the fastest-growing, vertically integrated cannabis companies in the U.S., focusing primarily on the California market [3]. - The company operates a range of brands, including Glass House Farms, PLUS Products, Allswell, and Mama Sue Wellness, alongside a network of retail dispensaries [3]. Event Details - The Investor Sesh IV will take place on June 20th at the Camarillo SoCal facility, which is noted as the largest cannabis farm in the U.S. [1][2]. - The event will provide opportunities for investors to engage in discussions about the company's growth, critical market developments, and its Phase III expansion plans [2]. Commitment to Shareholders - The company expresses its commitment to transparency and values the feedback from both retail and institutional investors [2]. - Attendees will have the chance to experience the facility firsthand, enjoy refreshments, and purchase exclusive merchandise and products [2].

Group 1 - Alan Brochstein is a pioneer in the cannabis investment sector, starting his career in the securities industry in 1986 and founding AB Analytical Services in 2007 to provide consulting for investment advisors [1] - He has been managing the investing group 420 Investor since 2013, focusing on publicly-traded cannabis stocks and moving the group to Seeking Alpha in 2023 [2] - The 420 Investor group covers 23 stocks, providing investment news, earnings report previews, and post-report analyses, along with model portfolios, weekly videos, summaries, and a monthly newsletter [2] Group 2 - The Big Picture is a sub-service of 420 Investor that helps investors stay informed about the cannabis sector [2]

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Canopy Growth Corporation (NASDAQ: CGC). Shareholders who purchased shares of CGC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of CGC during the timeframe listed a ...

Core Viewpoint - A class action lawsuit has been filed against Canopy Growth Corporation for allegedly misleading investors regarding its cost reduction measures and financial health during a specific period [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Canopy Growth Corporation failed to disclose significant costs associated with the production of Claybourne pre-rolled joints and indirect costs related to Storz & Bickel vaporizer devices, which negatively impacted the company's gross margins and overall financial results [2]. - Canopy announced disappointing financial results on February 7, 2025, attributing them to incremental costs from the Claybourne product launch and increased indirect costs from vaporizer devices, leading to a 27.24% drop in share price to $2.02 on the same day [3]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Canopy Growth Corporation, with a deadline to contact Robbins LLP for those wishing to serve as lead plaintiff by June 3, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Group 1 - cbdMD, Inc. will host a conference call on May 15, 2025, at 4:20 p.m. Eastern Time to discuss its financial results for the second quarter of fiscal year 2025, ending March 31, 2025 [1] - The company is recognized as one of the leading and most trusted CBD brands in the United States, offering a comprehensive line of THC-free CBD products and Delta 9 products compliant with the Farm Act [2][3] - cbdMD's product offerings include veterinarian-formulated pet products under the Paw CBD brand and functional mushroom products under the ATRx brand, as well as a THC-infused social seltzer called Herbal Oasis [2]

Core Insights - Vireo Growth Inc. reported Q1 revenue of $24.5 million, reflecting a 1.9% year-over-year increase, aligning with expectations for its established markets [1][2] - The company anticipates the closing of merger transactions in Q2, which is expected to enhance its profitability profile [1][4] Financial Performance - GAAP Revenue for Q1 2025 was $24.5 million, compared to $24.1 million in Q1 2024, marking a 1.9% increase [2] - GAAP Gross Profit reached $12.4 million, up from $12.2 million, with a Gross Profit Margin of 50.6%, slightly down from 50.8% [2] - SG&A Expenses increased to $7.5 million from $7.1 million, representing a 6.0% rise, and SG&A as a percentage of sales rose to 30.5% from 29.3% [2] - Operating Income decreased significantly to $2.0 million from $4.8 million, resulting in an Operating Income Margin drop to 8.1% from 19.8% [2] - Adjusted EBITDA improved to $6.6 million, an 8.5% increase from $6.1 million, with an Adjusted EBITDA Margin of 26.8% [2] Market Performance - Revenue growth was driven by continued expansion in Maryland, stable performance in Minnesota, and the initiation of adult-use sales in New York, despite a decline in medical sales in New York [3] - Retail revenue in Minnesota increased by 2% to $11.2 million, while New York saw a 34% decline to $1.2 million [22] - Wholesale revenue in Maryland rose by 22% to $4.1 million, contributing to an overall wholesale revenue increase of 18% [22] Balance Sheet and Liquidity - As of March 31, 2025, total current assets were $128.5 million, with cash on hand amounting to $86.3 million [3] - Total current liabilities were reported at $13.3 million, excluding New York assets held for sale [3] Merger Transactions - The company has filed a Definitive Information Circular regarding its proposed merger transactions and has received necessary shareholder approvals [4] - Regulatory approvals for proposed transactions in Utah have been obtained, with expectations to meet customary closing conditions in Q2 2025 [5]

Core Viewpoint - Stock splits can indicate a company's performance, with forward splits often seen positively, while reverse splits may signal struggles, as exemplified by Tilray Brands [1][2][4]. Group 1: Stock Splits - A forward stock split increases the number of shares for each investor, often indicating expected strong performance and making shares more affordable [2]. - A reverse stock split reduces the number of shares and increases the stock price proportionately, often used to avoid delisting from major exchanges [2][3]. Group 2: Tilray's Performance - Tilray has faced significant challenges, with its share price dropping below $1, currently at approximately $0.43, indicating a long-term downward trend [4]. - The company's financial results are disappointing, with revenue growth largely driven by acquisitions and consistent unprofitability [4][6]. - The legal landscape for cannabis remains difficult, with federal illegality in the U.S. and regulatory barriers in Canada hindering growth [6]. Group 3: Reverse Stock Split Proposal - Tilray announced a special stockholders' meeting to vote on a reverse stock split proposal, which is likely to be approved given the company's current situation [7]. - A reverse stock split would prevent delisting from Nasdaq but does not address the underlying business challenges [8]. Group 4: Future Prospects - Tilray has reduced its focus on cannabis and is now a leading craft brewer in the U.S., hoping for future federal legalization of cannabis [8]. - CEO Irwin Simon anticipates potential legalization during President Trump's second term, which could position Tilray favorably in the cannabis-infused drinks market [9]. - However, uncertainties remain regarding the timeline and specifics of legalization, which could limit market potential [9][10]. Group 5: Investment Outlook - Given the ongoing challenges and lack of attractive business prospects, Tilray is not considered an appealing investment opportunity [10].

Financial Data and Key Metrics Changes - First quarter revenue was $44.6 million, a modest increase of $200,000 or 1% compared to the prior year period, driven by growth in standard listings and display advertising [12][15] - Net income rose to $2.5 million from $2 million in the prior year, primarily due to mark-to-market adjustments on warrants and higher interest income [15] - Adjusted EBITDA for the first quarter was $10.1 million, exceeding expectations due to slightly higher revenue and lower expenses [15][16] - Cash from operations generated was $1.3 million, with a cash balance of $53.3 million, marking the seventh consecutive quarter of cash growth [15][16] Business Line Data and Key Metrics Changes - Growth in standard listings increased by $400,000, while display advertising grew by $800,000, offset by a $1 million decline in revenue from featured and deal listings [12][13] - Average monthly paying clients increased by 5% year over year to 5,179, but average monthly revenue per paying client declined to $2,871 from $2,997 [13] Market Data and Key Metrics Changes - Mature markets continue to show decreasing retail prices, leading to reduced cash flow for clients and impacting their ability to purchase services [8] - Emerging markets, while showing potential, remain subscale and do not compensate for challenges in mature markets [8] Company Strategy and Development Direction - The company is focused on disciplined execution, maintaining a lean cost structure, and driving ROI-driven investments [9] - Significant progress has been made in technology and product development, including improvements in data infrastructure and automation [10] - The marketing organization has been restructured to reconnect with the brand's heritage in the cannabis culture [10] Management's Comments on Operating Environment and Future Outlook - The regulatory environment remains challenging, with over-taxation and competition from unregulated hemp impacting the cannabis industry [5][6] - Management expresses cautious optimism about potential federal legalization, noting that a significant majority of Americans support it [7] - The company expects revenues for the second quarter to be approximately $45 million, with non-GAAP adjusted EBITDA estimated at $8 million [16] Other Important Information - GAAP operating expenses totaled $42 million, reflecting a 3% increase over the prior year, driven by higher general and administrative expenses [14] - The increase in G&A expenses included $2 million of non-recurring charges related to legal expenses and severance [14] - The company has no debt on its balance sheet, allowing for strategic investments despite ongoing industry challenges [15][16] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Canopy Growth Corporation ("Canopy Growth Corporation" or the "Company") (NASDAQ: CGC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Canopy Growth Corporation investors who were adversely affected by alleged securities fraud between May 30, 2024 and February 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zl ...